Most Read Articles
20 May 2019

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

31 May 2019
Co-therapy with proton pump inhibitors (PPIs) in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease confers no benefit for upper gastrointestinal events but may reduce bleeding due to gastroduodenal lesions, a study has shown.
Laura Kho Sui San , 29 May 2019
Anxiety becomes a pathological disorder when it occurs for no detectable reason, persists and interferes with daily activities like work performance and relationships.
Jairia Dela Cruz, 10 Jun 2019
Statins appear to exert neuroprotective effects in diabetic prostate cancer patients receiving androgen deprivation therapy (ADT), with a recent study showing that the drug confers benefit for the risk of dementia. The benefit is greater with higher statin adherence and intensity.

Tenofovir better than entecavir in acute-on-chronic liver failure due to CHB reactivation

15 Mar 2019

A recent study has shown that the short-term efficacy of tenofovir disoproxil fumarate (TDF) is superior to entecavir (ETV) for the treatment of acute-on-chronic-liver failure (ACLF) due to reactivation of chronic hepatitis B (CHB).

Moreover, white blood cell count and hepatitis B virus (HBV)-DNA reduction at 2 weeks independently predict mortality at 3 months.

At 2 weeks, patients in the TDF vs ETV group had significantly higher HBV-DNA reduction (p=0.003), lower HBV-DNA level (p=0.001), higher rate of HBV-DNA undetectability (p=0.007), lower Child-Turcotte-Pugh (CTP; p=0.003) and model for end-stage liver disease scores (p=0.002).

At 3 months, all survivors had undetectable HBV-DNA, while CTP (p=0.970) and model for end-stage liver disease scores (p=0.192) were comparable between the two groups but markedly lower compared with baseline values (p<0.01). In addition, cumulative survival rate was significantly higher in the TDF vs ETV group (p=0.025).

White blood cell count (hazard ratio [HR], 2.726; 95 percent CI, 2.691–7.897; p=0.000) and HBV-DNA reduction (HR, 0.266; 0.033–0.629; p=0.013) at 2 weeks independently predicted mortality. The two study drugs were well tolerated.

In this study, a total of 67 consecutive patients with HBV-ACLF were assigned to groups receiving daily TDF (300 mg/d; n=32) or daily ETV (0.5 mg/d; n=35). Researchers prospectively followed these patients. Overall survival at 3 months was the primary endpoint.

“ACLF can be triggered by reactivation of CHB. TDF and ETV are now the most potent antiviral agents for CHB,” according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
20 May 2019

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

31 May 2019
Co-therapy with proton pump inhibitors (PPIs) in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease confers no benefit for upper gastrointestinal events but may reduce bleeding due to gastroduodenal lesions, a study has shown.
Laura Kho Sui San , 29 May 2019
Anxiety becomes a pathological disorder when it occurs for no detectable reason, persists and interferes with daily activities like work performance and relationships.
Jairia Dela Cruz, 10 Jun 2019
Statins appear to exert neuroprotective effects in diabetic prostate cancer patients receiving androgen deprivation therapy (ADT), with a recent study showing that the drug confers benefit for the risk of dementia. The benefit is greater with higher statin adherence and intensity.